Logo image
Back
Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration
Journal article   Open access   Peer reviewed

Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration

Gui-shuang Ying, Jiayan Huang, Maureen G Maguire, Glenn J Jaffe, Juan E Grunwald, Cynthia Toth, Ebenezer Daniel, Michael Klein, Dante Pieramici, John Wells, …
Ophthalmology (Rochester, Minn.), Vol.120(1), pp.122-129
01/2013
DOI: 10.1016/j.ophtha.2012.07.042
PMCID: PMC3536921
PMID: 23047002
url
https://www.ncbi.nlm.nih.gov/pmc/articles/3536921View
Open Access

Abstract

To determine the baseline predictors of visual acuity (VA) outcomes 1 year after treatment with ranibizumab or bevacizumab for neovascular age-related macular degeneration (AMD). Cohort study within the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). A total of 1105 participants with neovascular AMD, baseline VA 20/25 to 20/320, and VA measured at 1 year. Participants were randomly assigned to ranibizumab or bevacizumab on a monthly or as-needed schedule. Masked readers evaluated fundus morphology and features on optical coherence tomography (OCT). Visual acuity was measured using electronic VA testing. Independent predictors were identified using regression techniques. The VA score, VA score change from baseline, and ≥3-line gain at 1 year. At 1 year, the mean VA score was 68 letters, mean improvement from baseline was 7 letters, and 28% of participants gained ≥3 lines. Older age, larger area of choroidal neovascularization (CNV), and elevation of retinal pigment epithelium (RPE) were associated with worse VA (all P<0.005), less gain in VA (all P<0.02), and a lower proportion gaining ≥3 lines (all P<0.04). Better baseline VA was associated with better VA at 1 year, less gain in VA, and a lower proportion gaining ≥3 lines (all P<0.0001). Predominantly or minimally classic lesions were associated with worse VA than occult lesions (66 vs. 69 letters; P=0.0003). Retinal angiomatous proliferans (RAP) lesions were associated with more gain in VA (10 vs. 7 letters; P=0.03) and a higher proportion gaining ≥3 lines (odds ratio, 1.9; 95% confidence interval, 1.2-3.1). Geographic atrophy (GA) was associated with worse VA (64 vs. 68 letters; P=0.02). Eyes with total foveal thickness in the second quartile (325-425 μm) had the best VA (P=0.01) and were most likely to gain ≥3 lines (P=0.004). Predictors did not vary by treatment group. For all treatment groups, older age, better baseline VA, larger CNV area, predominantly or minimally classic lesion, absence of RAP lesion, presence of GA, greater total fovea thickness, and RPE elevation on optical coherence tomography were independently associated with less improvement in VA at 1 year. The author(s) have no proprietary or commercial interest in any materials discussed in this article.
 Antibodies, Monoclonal, Humanized - therapeutic use Intravitreal Injections Tomography, Optical Coherence Humans Middle Aged Male Treatment Outcome Wet Macular Degeneration - physiopathology Vascular Endothelial Growth Factor A - antagonists & inhibitors Bevacizumab Wet Macular Degeneration - drug therapy Time Factors Ranibizumab Aged, 80 and over Angiogenesis Inhibitors - therapeutic use Female Aged Visual Acuity - physiology Cohort Studies Fluorescein Angiography

Details

Metrics

24 Record Views
274 Times Cited - Web of Science
Logo image